Tata Consultancy Services (TCS) (BSE: 532540, NSE: TCS) has been positioned as a Leader in the IDC MarketScape for Worldwide Life Science Sales and Marketing IT Outsourcing Services.
According to the report, "TCS has extensive experience in the life sciences industry, with a large number of customers in the pharmaceutical and biotech space, complemented by a large number of medical device customers." It goes on to say that "TCS has diversified its life sciences customer portfolio with its consultingled offerings, and the majority of the business is from the large companies with revenue exceeding $1 billion."
"With our deep domain knowledge, investments in intellectual property and comprehensive suite of mar-tech solutions and services, we are helping life sciences customers harness the power of digital technologies in transforming their sales and marketing to drive business growth," said Vikram Karakoti, Business Head, Life Sciences, TCS. "This recognition reflects our vision, strategies, innovation efforts, and capabilities to enable superior business outcomes for our customers."
TCS collaborates with leading life sciences companies across the world to enable their digital transformation journeys. The company provides a full set of advisory and IT services and solutions across the life sciences value chain, including data and analytics, predictive and prescriptive analytics, genomics research, blockchain enabled clinical supply chain, AI enabled case processing, discovery collaboration, cognitive research, and digital labs. These solutions use a combination of cognitive computing capabilities, artificial intelligence, Internet of Things, robotic process automation and cloud to fully digitalize the life sciences value chain.
TCS' sales and marketing services help life sciences companies drive transformations across CRM, sales force automation, analytics and insights, physician targeting, incentive and compensation management, e-learning and training, digital asset management, system validation, aggregate spend compliance, e-marketing, and collaboration services.
TCS heavily invests in research and innovation to help customers stay ahead of the curve. Its genomics labs offer capabilities such as DNA sequencing, translation research and marker validation. The TCS ADD platform reimagines the end-to-end drug development enhancing patient experience and making clinical trials more safe and agile. TCS' Innovation Labs provide an ideal environment for research in cutting-edge technologies across domains. It also drives various solutions to accelerate the deployment of new business capabilities.
Michael Townsend, Research Director, Life Sciences Commercial Strategies, IDC, said, "Digital transformation is occurring at a rapid pace in life science companies, including in the sales and marketing space. TCS has demonstrated strong investments in the life science sales and marketing space, enabled by IPbased digital solution and products, helping it earn a position as a Leader."
Shares of Tata Consultancy Services Limited was last trading in BSE at Rs. 3544.65 as compared to the previous close of Rs. 3547.70. The total number of shares traded during the day was 71786 in over 5766 trades.
The stock hit an intraday high of Rs. 3587.30 and intraday low of 3520.00. The net turnover during the day was Rs. 254890694.00.